标题
Targeting Interleukin-6 in Rheumatoid Arthritis
作者
关键词
Rheumatoid Arthritis Patient, Juvenile Idiopathic Arthritis, Tocilizumab, Tumour Necrosis Factor Inhibitor, Radiographic Progression
出版物
DRUGS
Volume 73, Issue 4, Pages 341-356
出版商
Springer Nature
发表日期
2013-03-01
DOI
10.1007/s40265-013-0018-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?
- (2012) Anne M Kerola et al. ANNALS OF THE RHEUMATIC DISEASES
- Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
- (2012) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
- (2012) P Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab – A novel therapy for non-organ-specific autoimmune diseases
- (2012) Lisa Kaly et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- The role of tocilizumab in the management of rheumatoid arthritis
- (2012) Zoe Ash et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Assessing the safety of biologic agents in patients with rheumatoid arthritis
- (2012) A. Rubbert-Roth RHEUMATOLOGY
- Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica
- (2012) S. Unizony et al. ARTHRITIS CARE & RESEARCH
- Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study
- (2011) Yusuf Yazici et al. ANNALS OF THE RHEUMATIC DISEASES
- Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
- (2011) S. I. Grivennikov et al. ANNALS OF THE RHEUMATIC DISEASES
- Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
- (2011) M. M. Soliman et al. ANNALS OF THE RHEUMATIC DISEASES
- 2011 ACR/ARHP Annual Scientific Meeting Late-Breaking Abstracts
- (2011) ARTHRITIS AND RHEUMATISM
- The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment
- (2011) Ning Li et al. CANCER CELL
- Tocilizumab treatment for neuro-Behcet's disease, the first report
- (2011) Lee S. Shapiro et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Evaluating disease activity in rheumatoid arthritis: Which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI
- (2011) Cécile Gaujoux-Viala et al. JOINT BONE SPINE
- A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab
- (2011) Toru Hirano et al. Modern Rheumatology
- Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody
- (2011) K. Sumida et al. RHEUMATOLOGY
- Therapeutic effect of tocilizumab on two patients with polymyositis
- (2011) M. Narazaki et al. RHEUMATOLOGY
- Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI
- (2011) Atsushi Kaneko et al. RHEUMATOLOGY INTERNATIONAL
- Integrated safety in tocilizumab clinical trials
- (2011) Michael H Schiff et al. ARTHRITIS RESEARCH & THERAPY
- Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
- (2010) G. R. Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants
- (2010) Josef S. Smolen et al. ARTHRITIS AND RHEUMATISM
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study
- (2010) Gabor G. Illei et al. ARTHRITIS AND RHEUMATISM
- Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
- (2010) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Comparison of composite disease activity indices for rheumatoid arthritis
- (2010) Toshihiro Matsui et al. Modern Rheumatology
- The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
- (2010) Y. Shima et al. RHEUMATOLOGY
- Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
- (2010) L. Campbell et al. RHEUMATOLOGY
- Tocilizumab in refractory adult Still's disease
- (2010) Xavier Puéchal et al. ARTHRITIS CARE & RESEARCH
- The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis
- (2010) Srinivasan Srirangan et al. Therapeutic Advances in Musculoskeletal Disease
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
- (2009) G. Jones et al. ANNALS OF THE RHEUMATIC DISEASES
- Demyelinating events in rheumatoid arthritis after drug exposures
- (2009) S. Bernatsky et al. ANNALS OF THE RHEUMATIC DISEASES
- Total cholesterol and LDL levels decrease before rheumatoid arthritis
- (2009) E. Myasoedova et al. ANNALS OF THE RHEUMATIC DISEASES
- Leukoencephalopathy with Cognitive Impairment following Tocilizumab for the Treatment of Rheumatoid Arthritis (RA)
- (2009) Katsuya Kobayashi et al. INTERNAL MEDICINE
- Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
- (2008) N Nishimoto et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus
- (2008) Sahena Haque et al. CURRENT OPINION IN LIPIDOLOGY
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
- (2008) Josef S Smolen et al. LANCET
- Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
- (2008) Norihiro Nishimoto et al. Modern Rheumatology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now